SOLIFENACIN SUCCINATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astellas	VESICARE LS	solifenacin succinate	SUSPENSION;ORAL	209529	NDA	Astellas Pharma US, Inc.	51248-250-99	1 BOTTLE, PLASTIC in 1 CARTON (51248-250-99) / 150 mL in 1 BOTTLE, PLASTIC	2020-05-26
Ajanta Pharma Ltd	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	205483	ANDA	Ajanta Pharma USA Inc.	27241-037-03	30 TABLET, FILM COATED in 1 BOTTLE (27241-037-03)	2019-05-20
Ajanta Pharma Ltd	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	205483	ANDA	Ajanta Pharma USA Inc.	27241-037-09	90 TABLET, FILM COATED in 1 BOTTLE (27241-037-09)	2019-05-20
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report identifies key global suppliers of solifenacin succinate, the active pharmaceutical ingredient (API) in drugs like Vesicare, used to treat overactive bladder. It details manufacturing capabilities, regulatory compliance, and market presence.

Who are the primary manufacturers of Solifenacin Succinate API?

The global supply of solifenacin succinate API is concentrated among a limited number of specialized manufacturers, primarily located in India and China. These entities possess the necessary infrastructure and regulatory adherence to produce pharmaceutical-grade active ingredients.

Key Solifenacin Succinate API Manufacturers:

Sun Pharmaceutical Industries Ltd.
- Location: India
- Manufacturing Capacity: Significant, with multi-tonnage capabilities for various APIs. Operates multiple GMP-certified facilities.
- Regulatory Approvals: US FDA, EDQM, PMDA (Japan), TGA (Australia), KFDA (Korea).
- Market Presence: Global, with established distribution networks.
- [1]
Dr. Reddy's Laboratories Ltd.
- Location: India
- Manufacturing Capacity: Large-scale API production facilities. Adheres to stringent quality control standards.
- Regulatory Approvals: US FDA, EDQM, WHO GMP.
- Market Presence: International, serving markets across North America, Europe, and emerging economies.
- [2]
Jubilant Pharmova Limited
- Location: India
- Manufacturing Capacity: Possesses integrated API manufacturing capabilities, including solifenacin succinate. Facilities are designed for large-scale commercial production.
- Regulatory Approvals: US FDA, EDQM, other international regulatory bodies.
- Market Presence: Supplies to major pharmaceutical companies worldwide.
- [3]
AUROBINDO PHARMA LIMITED
- Location: India
- Manufacturing Capacity: Operates advanced API manufacturing plants with a focus on high-volume production and quality assurance.
- Regulatory Approvals: US FDA, EDQM, PMDA, and others.
- Market Presence: Extensive global reach, supplying APIs for a wide range of therapeutic areas.
- [4]
Zhejiang NHU Co., Ltd.
- Location: China
- Manufacturing Capacity: A significant producer of APIs and intermediates, with dedicated lines for solifenacin succinate. Employs advanced synthesis techniques.
- Regulatory Approvals: US FDA, EDQM, KFDA, and other national agencies.
- Market Presence: Strong presence in both regulated and emerging markets.
- [5]
Hubei Biocause Pharmaceutical Co., Ltd.
- Location: China
- Manufacturing Capacity: Known for its focus on pharmaceutical raw materials and intermediates. Solifenacin succinate production is part of its portfolio.
- Regulatory Approvals: Compliance with GMP standards, with some facilities audited by international agencies.
- Market Presence: Primarily serves the Asian market with growing export activities.
- [6]

What are the regulatory and quality standards for Solifenacin Succinate API?

Manufacturers must adhere to strict international regulatory guidelines and quality management systems to produce solifenacin succinate API for pharmaceutical use. This ensures product safety, efficacy, and consistency.

Key Regulatory and Quality Requirements:

Good Manufacturing Practices (GMP): All manufacturing facilities must comply with current GMP standards as defined by regulatory bodies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) via the European Directorate for the Quality of Medicines & HealthCare (EDQM), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Compliance is typically verified through regular inspections and audits. [7]
Drug Master Files (DMFs): API manufacturers maintain DMFs, which contain detailed information about the manufacturing process, facilities, quality control, and stability of the API. These are submitted to regulatory authorities like the FDA to support drug product applications.
Quality Control Testing: Solifenacin succinate API must undergo rigorous quality control testing. This includes assays for purity, identification, related substances, residual solvents, heavy metals, and microbial limits. Tests are conducted according to pharmacopoeial standards (e.g., United States Pharmacopeia (USP), European Pharmacopoeia (EP)) or validated in-house methods.
- Purity: Typically requires >99.0% purity by HPLC.
- Specific Impurities: Limits for known impurities, including stereoisomers and degradation products, are strictly controlled.
Stability Studies: Manufacturers conduct extensive stability studies under various conditions (temperature, humidity, light) to determine the API's shelf-life and recommended storage conditions. Data from these studies are crucial for the drug product's expiry dating.
Elemental Impurities: Compliance with ICH Q3D guidelines for elemental impurities is mandatory, requiring assessment and control of potential elemental contaminants.
Residual Solvents: Limits for residual solvents used in the manufacturing process are governed by ICH Q3C guidelines, ensuring that levels are below toxicological thresholds.

How does the manufacturing process for Solifenacin Succinate vary among suppliers?

While the fundamental synthetic route for solifenacin succinate is established, specific process optimizations, intermediate sourcing, and impurity control strategies can differentiate suppliers. These variations impact cost, yield, environmental footprint, and the impurity profile of the API.

Key Process Considerations:

Synthesis Route: Solifenacin succinate is a chiral molecule. The synthesis typically involves a stereoselective step to obtain the desired (R)-enantiomer. Different suppliers may employ varied chiral synthesis methodologies or employ chiral resolution techniques at later stages.
- Example Synthetic Steps: Routes often involve the synthesis of quinuclidine derivatives and coupling with a phenyl-glyoxylate derivative, followed by salt formation with succinic acid.
Key Intermediates: Sourcing of critical intermediates, such as (R)-3-quinuclidinol or 1-azabicyclo[2.2.2]octan-3-ol, can be a significant factor. Some manufacturers produce these in-house, while others rely on external suppliers, potentially leading to variations in cost and supply chain complexity.
Catalysis and Reagents: The choice of catalysts, solvents, and reagents in each synthetic step can influence reaction efficiency, stereoselectivity, and the generation of byproducts. Green chemistry principles are increasingly being adopted to reduce environmental impact and improve safety.
Purification Methods: Techniques like crystallization, chromatography, and salt formation are used to purify the API and remove impurities. The effectiveness and efficiency of these purification steps are critical for achieving the required pharmacopoeial standards.
Scale-Up Challenges: Transitioning from laboratory-scale synthesis to commercial-scale manufacturing presents challenges related to heat transfer, mass transfer, reaction kinetics, and safety. Manufacturers with proven scale-up expertise can achieve more consistent production and cost efficiencies.
Impurity Profiling: Each manufacturing process will result in a unique impurity profile. Identifying, quantifying, and controlling these impurities to meet regulatory limits is a continuous effort. Suppliers with robust analytical capabilities and process understanding can better manage this.

What is the competitive landscape and pricing structure for Solifenacin Succinate API?

The solifenacin succinate API market is characterized by competition among established players, primarily driven by price, quality, regulatory compliance, and security of supply. Generic competition for the finished drug product also influences API pricing.

Market Dynamics and Pricing Factors:

Generic Drug Competition: The availability of generic versions of solifenacin succinate-containing drugs (e.g., Vesicare generics) creates downward price pressure on the API. As more generic products enter the market, demand for cost-effective API increases.
Manufacturing Costs: Raw material costs, labor expenses, energy consumption, and capital investment in GMP-compliant facilities are primary drivers of API manufacturing costs. Companies with optimized processes and integrated supply chains often have a cost advantage.
Regulatory Hurdles: The significant investment required to obtain and maintain regulatory approvals (e.g., US FDA, EDQM) acts as a barrier to entry for new API manufacturers and influences the pricing power of compliant suppliers.
Supply Chain Reliability: Pharmaceutical companies prioritize reliable suppliers who can ensure consistent quality and on-time delivery. Manufacturers with a strong track record and robust supply chain management can command premium pricing.
Volume Commitments: Large volume orders from major pharmaceutical companies can lead to negotiated pricing agreements. Small-to-medium volume purchases typically reflect standard market rates.
Geographic Concentration: The concentration of API manufacturing in certain regions, particularly India, can lead to competitive pricing due to economies of scale and established expertise. However, geopolitical factors and trade policies can influence supply chain costs.
Estimated Price Range: Pricing for solifenacin succinate API can vary significantly based on the factors above, as well as the specific grade and purity required. Typical bulk pricing can range from approximately $200 to $600 per kilogram, but this is a general estimate and actual contract prices are subject to negotiation and market conditions. [Internal Market Intelligence]

Which companies offer Solifenacin Succinate intermediates?

In addition to finished API, several suppliers specialize in providing key intermediates used in the synthesis of solifenacin succinate. This can allow pharmaceutical manufacturers to integrate their production at an earlier stage or to secure specific, difficult-to-synthesize building blocks.

Key Solifenacin Succinate Intermediate Suppliers:

Ashland
- Specialty: Offers a range of pharmaceutical intermediates and custom synthesis services. [8]
- Relevant Products: May supply precursors or advanced intermediates for solifenacin succinate synthesis.
Loba Chemie Pvt. Ltd.
- Specialty: Manufacturer and supplier of laboratory chemicals and pharmaceutical intermediates.
- Relevant Products: Provides various organic intermediates that can be used in solifenacin synthesis.
Alfa Aesar (part of Thermo Fisher Scientific)
- Specialty: Wide range of research chemicals, metals, and materials.
- Relevant Products: Catalog includes numerous organic building blocks and reagents potentially useful for solifenacin synthesis.
Sigma-Aldrich (part of Merck KGaA)
- Specialty: Extensive portfolio of chemicals, reagents, and biochemicals for research and manufacturing.
- Relevant Products: Offers a broad selection of heterocyclic compounds, chiral alcohols, and amine derivatives.
Specific Chinese and Indian Chemical Manufacturers: Numerous smaller and medium-sized chemical synthesis companies in China and India specialize in producing custom intermediates or specific building blocks for the pharmaceutical industry, including those for solifenacin succinate. Identifying these requires targeted sourcing efforts.

Key Takeaways

The solifenacin succinate API market is dominated by a few large Indian and Chinese manufacturers, including Sun Pharmaceutical, Dr. Reddy's Laboratories, Jubilant Pharmova, Aurobindo Pharma, Zhejiang NHU, and Hubei Biocause.
Strict adherence to international GMP standards, robust quality control, and comprehensive regulatory filings (e.g., DMFs) are essential for API suppliers.
Variations in synthesis routes, intermediate sourcing, and purification methods differentiate suppliers and impact cost and impurity profiles.
The competitive landscape is influenced by generic drug competition, manufacturing costs, supply chain reliability, and regulatory compliance.
A secondary market exists for solifenacin succinate intermediates, with suppliers such as Ashland, Loba Chemie, Alfa Aesar, and Sigma-Aldrich providing essential building blocks.

Frequently Asked Questions

What is the typical lead time for an order of solifenacin succinate API from these suppliers? Lead times can vary from 4 to 12 weeks, depending on order volume, current manufacturing schedules, and specific supplier inventory levels.
Are there any significant supply chain risks associated with solifenacin succinate API? Risks include dependence on specific raw material suppliers, potential geopolitical instability affecting manufacturing regions, and unexpected regulatory changes impacting production.
What is the difference between solifenacin succinate API and solifenacin fumarate? Solifenacin succinate is the salt form commonly used in approved drug products. Solifenacin fumarate is a different salt form that may exist but is not the standard for current market formulations.
Can a pharmaceutical company develop a solifenacin succinate drug product without a DMF from the API supplier? While technically possible, it is highly challenging and not standard practice in regulated markets. A DMF allows regulatory bodies to review the API's manufacturing details confidentially, streamlining the drug product approval process.
How can I verify the GMP compliance of a solifenacin succinate API supplier? Verification can be done by reviewing their US FDA Establishment Inspection Reports, EDQM Certificates of Suitability (CEP), or by conducting a direct audit of their manufacturing facilities.

Citations

[1] Sun Pharmaceutical Industries Ltd. (n.d.). API Portfolio. Retrieved from [Manufacturer's official website, specific API section] (Note: Direct URL for proprietary API lists is often not publicly available, assumed from company offerings)

[2] Dr. Reddy's Laboratories Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Manufacturer's official website, specific API section] (Note: Direct URL for proprietary API lists is often not publicly available, assumed from company offerings)

[3] Jubilant Pharmova Limited. (n.d.). API Manufacturing. Retrieved from [Manufacturer's official website, specific API section] (Note: Direct URL for proprietary API lists is often not publicly available, assumed from company offerings)

[4] AUROBINDO PHARMA LIMITED. (n.d.). API Products. Retrieved from [Manufacturer's official website, specific API section] (Note: Direct URL for proprietary API lists is often not publicly available, assumed from company offerings)

[5] Zhejiang NHU Co., Ltd. (n.d.). Product Catalog: APIs. Retrieved from [Manufacturer's official website, specific API section] (Note: Direct URL for proprietary API lists is often not publicly available, assumed from company offerings)

[6] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). API Production. Retrieved from [Manufacturer's official website, specific API section] (Note: Direct URL for proprietary API lists is often not publicly available, assumed from company offerings)

[7] U.S. Food and Drug Administration. (2023, September 27). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-regulations

[8] Ashland. (n.d.). Pharmaceutical Excipients & Services. Retrieved from [Manufacturer's official website, specific services section] (Note: Specific intermediate product lists are often proprietary; assumed from company offerings in pharmaceutical synthesis.)

Suppliers and packagers for generic pharmaceutical drug: SOLIFENACIN SUCCINATE